In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of Emergent Biosolutions Inc (NYSE: EBS) was $10.34 for the day, up 2.48% from the previous closing price of $10.09. In other words, the price has increased by $2.48 from its previous closing price. On the day, 1.32 million shares were traded. EBS stock price reached its highest trading level at $10.37 during the session, while it also had its lowest trading level at $9.91.
Ratios:
Our analysis of EBS’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 2.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 387.90. For the most recent quarter (mrq), Quick Ratio is recorded 3.15 and its Current Ratio is at 5.76. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.15.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On August 22, 2024, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $16.
The Benchmark Company Upgraded its Hold to Buy on March 07, 2024, while the target price for the stock was maintained at $5.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 07 ’25 when Glessner Coleen sold 30,608 shares for $10.00 per share. The transaction valued at 306,080 led to the insider holds 144,319 shares of the business.
COLEEN GLESSNER bought 30,608 shares of EBS for $306,080 on Oct 07 ’25. On Aug 15 ’25, another insider, Zoon Kathryn C, who serves as the Director of the company, sold 7,086 shares for $8.87 each. As a result, the insider received 62,853 and left with 71,799 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EBS now has a Market Capitalization of 543056448 and an Enterprise Value of 968556416. As of this moment, Emergent’s Price-to-Earnings (P/E) ratio for their current fiscal year is 7.99. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.69 while its Price-to-Book (P/B) ratio in mrq is 0.94. Its current Enterprise Value per Revenue stands at 1.228 whereas that against EBITDA is 4.413.
Stock Price History:
The Beta on a monthly basis for EBS is 2.34, which has changed by -0.08272725 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, EBS has reached a high of $13.41, while it has fallen to a 52-week low of $4.02. The 50-Day Moving Average of the stock is 14.49%, while the 200-Day Moving Average is calculated to be 39.28%.
Shares Statistics:
EBS traded an average of 1.25M shares per day over the past three months and 1996690 shares per day over the past ten days. A total of 52.70M shares are outstanding, with a floating share count of 50.45M. Insiders hold about 3.94% of the company’s shares, while institutions hold 76.30% stake in the company. Shares short for EBS as of 1760486400 were 8830216 with a Short Ratio of 7.08, compared to 1757894400 on 8857827. Therefore, it implies a Short% of Shares Outstanding of 8830216 and a Short% of Float of 16.93.
Earnings Estimates
Investors are keenly observing as 2.0 analysts analyze and rate. The current performance of Emergent Biosolutions Inc (EBS) in the stock market.The consensus estimate for the next quarter is $0.98, with high estimates of $0.98 and low estimates of $0.98.
Analysts are recommending an EPS of between $1.34 and $1.19 for the fiscal current year, implying an average EPS of $1.26. EPS for the following year is -$0.45, with 1.0 analysts recommending between -$0.45 and -$0.45.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 2 analysts. It ranges from a high estimate of $220M to a low estimate of $215M. As of. The current estimate, Emergent Biosolutions Inc’s year-ago sales were $194.7MFor the next quarter, 2 analysts are estimating revenue of $275M. There is a high estimate of $275M for the next quarter, whereas the lowest estimate is $275M.
A total of 2 analysts have provided revenue estimates for EBS’s current fiscal year. The highest revenue estimate was $809.6M, while the lowest revenue estimate was $809.2M, resulting in an average revenue estimate of $809.4M. In the same quarter a year ago, actual revenue was $1.04BBased on 2 analysts’ estimates, the company’s revenue will be $932.75M in the next fiscal year. The high estimate is $1.16B and the low estimate is $710.5M.
